Fusion protein vaccine platform for HIV and coronaviruses
This technology uses bacteria that have been engineered to carry and display viral proteins on their surface, while also having large portions of their own genome removed to make them simpler and less distracting to the immune system. When injected or administered, these stripped-down bacteria act as a delivery vehicle that trains the immune system to recognize and attack dangerous viruses like HIV, SARS-CoV-2, influenza, and Ebola. The reduced genome appears to help the immune system focus more sharply on the viral target rather than the bacterial carrier itself, producing a stronger and more specific antibody response. This is essentially a novel vaccine platform technology applicable across an entire family of hard-to-vaccinate viruses.
What you could build
A next-generation vaccine platform company would license this to develop vaccines against HIV, pandemic influenza, or future coronaviruses; the primary buyers would be large pharmaceutical vaccine manufacturers and government pandemic preparedness agencies seeking alternatives to mRNA and protein-subunit approaches.
Who in Virginia should care
Virginia-based defense and federal health contractors—particularly those with BARDA, NIH, or DARPA relationships—as well as biotech spinouts from Virginia research universities would be natural early partners or licensees given federal pandemic preparedness funding flows through the region.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Steven L. Zeichner, Xiang-Jin Meng, Debin Tian
- Filed
- Patent pending — filed November 11, 2022
- Status
- Application
- Publication number
- US20240261394A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.